PWSA | USA received the news that Radius Health has decided to end its phase 2/3 clinical trial to evaluate RAD011 as a potential treatment for Prader-Willi syndrome (PWS). Radius was recently purchased by Gurnet Point Capital, who shared it will begin winding down the SCOUT-015 study throughout the month of October.
On behalf of Radius Health:
"Radius was founded with the goal of addressing unmet medical needs and improving the lives of patients through the development and commercialization of new treatments, and we understand how difficult this decision is for enrolled patients, their families, and their caregivers. We are working closely with our research partners to help ensure that those enrolled in the trial are supported during this closeout."
We know the past year has been tough on our community from a clinical trial standpoint, and PWSA | USA is here to support our families. Please reach out to us if you need assistance or support at 941-312-0400 or .